About Us | Contact Us |        

A Clinical Analysis of ASH 2013 Data: Focus on Myelofibrosis

1 AMA PRA Category 1 Credit(s)
Launch Date:
February 25, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

hematologists, Hematologists/Oncologists

Relevant Terms:

Myelofibrosis, Myeloproliferative Neoplasms, Polycythemia Vera

Ruben Mesa, MD

Ruben Mesa, MD
Professor of Medicine
Mayo Clinic
Scottsdale, AZ

Ruben Mesa, MD, is Professor of Medicine, Chair of the Hematologic Malignancy Disease Oriented Group, and Director of the Acute and Chronic Leukemias Program in the Division of Hematology-Oncology at Mayo Clinic in Arizona. Dr. Mesa is board certified in internal medicine, hematology, and medical oncology.  He founded the biennial Mayo Clinic Living With a Blood Disease Symposium for patients with hematologic diseases and is active with the International Working Group for Myelofibrosis Research and Treatment and with the MPD Research Consortium. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American College of Physicians. Dr. Mesa's primary field of interest is hematology, with a focus on acute and chronic leukemia and, more specifically, chronic myeloproliferative neoplasms (MPNs). His research is centered on evaluating novel therapeutics, implementing clinical trials, and working on quality of life studies concerning MPNs.

Vikas Gupta, MD, FRCP, FRCPath

Vikas Gupta, MD, FRCP, FRCPath
Associate Professor, Department of Medicine
Staff Physician, Leukemia/BMT Programs
The Princess Margaret Cancer Centre
Toronto, Canada

Dr. Gupta is a distinguished hematologist at the Princess Margaret Cancer Centre in Toronto, Ontario. His research interests include novel therapeutics in Philadelphia-negative myeloproliferative neoplasms and transplantation for myeloid malignancies. Dr. Gupta has authored numerous publications focusing upon myeloproliferative disorders. He currently serves as an Associate Professor at the University of Toronto Department of Medicine.
1. Identify the most recent diagnostic criteria, management recommendations, prognostic variables, and treatment paradigms for myelofibrosis (MF)
2. Identify treatments for both primary MF and MF due to transformed ET and PV, including approved and investigational agents targeting both JAK/STAT and other novel pathways

Instructions on How to Receive Credit
  • Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
  • Complete the post-test and evaluation.
  • After passing the post-test, print out your electronic CE certificate.
  • In order to successfully complete this activity learners must achieve a minimum of 70% on the post-test.
This activity is supported by unrestricted educational grants from Incyte and sanofi-aventis.

This activity is sponsored by the Institute for Continuing Healthcare Education.
Accreditation Statements
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Institute for Continuing Healthcare Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
It is the policy of the Institute to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All persons in control of content must disclose any significant financial interest or other relationships that may affect the content of this activity.

Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.
Ruben A. Mesa, MD
Professor of Medicine
Mayo Clinic
Scottsdale, AZ
Dr. Mesa has disclosed the following relevant financial relationships that have occurred within the past 12 months: Novartis/C; Gilead, Genentech, Incyte, Lily, NS Pharma, Pfizer/G.
Vikas Gupta, MD, FRCP, FRCPath
Associate Professor, Department of Medicine
Staff Physician, Leukemia/BMT Programs
The Princess Margaret Cancer Centre
Toronto, Canada
Dr. Gupta has disclosed the following relevant financial relationships that have occurred within the past 12 months: Incyte, Novartis/A, G; Novartis/C, SB.
Peer Reviewer
Brady L. Stein, MD, MHS
Assistant Professor, Medicine
Hematology Oncology Division
Feinberg School of Medicine
Northwestern University
Chicago, IL
Dr. Stein has disclosed the following relevant financial relationships that have occurred within the past 12 months: Incyte/A, SB; Roche/H.
Activity Development and Management Team
Cathy Pagano, CCMEP; Scott Kober, MBA, CCMEPSandra Davidson; and Megan Small are employees of the Institute for Continuing Healthcare Education (the Institute) and have no relationships to disclose.
Off-label Product Disclosure
This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
For additional technical support, please send an email to msmall@iche.edu.
General Disclosure and Copyright Statement
The opinions expressed in this publication are those of the participating faculty and not those of the Institute, Incyte, sanofi-aventis, or any manufacturers of products mentioned herein.
This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.
Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.
Copyright 2014. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.